13F Holdings
中文EN

BMEA Biomea Fusion, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1840439 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY76.7%
TTM EPS YoY95.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-192.3%
ROA-53.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets73.0%
Debt / equity0.00x
Current ratio2.17x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.98x
Accruals ratio52.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$61.98M$118.08M$102.55M$62.71M$28.00M
SG&A expense$19.33M$25.98M$23.59M$20.92M$13.67M
Operating income-$83.51M-$144.07M-$126.14M-$83.63M-$41.67M
Income tax$0$0$0$0$0
Net income-$61.80M-$138.43M-$117.25M-$81.83M-$41.57M
EBITDA-$82.10M-$142.32M-$124.62M-$82.94M-$41.42M
EPS (basic)-1.18-3.83-3.44-2.80-1.74
EPS (diluted)-1.18-3.83-3.44-2.80-1.74
Weighted avg. shares (diluted)52.23M36.11M34.11M29.27M23.86M
Banking
Net interest income$1.86M$5.64M$8.88M——
Balance sheet
Cash & equivalents$55.81M$58.65M$176.87M$112.25M$146.09M
Short-term investments———$1.15M$27.78M
Current assets$58.05M$68.33M$179.18M$117.82M$176.56M
PP&E, net$153,000$3.77M$5.16M$5.84M$2.96M
Total assets$58.57M$79.94M$199.93M$129.31M$185.71M
Current liabilities$11.10M$21.67M$22.86M$19.10M$4.64M
Total liabilities$29.02M$28.36M$30.69M$20.77M$6.92M
Shareholders' equity$29.55M$51.57M$169.24M$108.54M$178.78M
Shares outstanding72.30M36.31M35.87M29.56M29.12M
Cash flow statement
Operating cash flow-$70.37M-$119.89M-$96.59M-$62.42M-$35.44M
Capital expenditure—$362,000$3.37M$1.03M$3.17M
Free cash flow—-$120.26M-$99.96M-$63.45M-$38.61M
Investing cash flow—-$362,000-$2.22M$27.34M-$33.35M
Financing cash flow$67.90M$1.67M$163.80M$1.24M$153.19M
Depreciation & amortization$1.41M$1.75M$1.51M$691,000$249,000
Stock-based compensation$9.52M$19.09M$14.13M$10.34M$6.23M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.